Lancashire and South Cumbria
Formulary
Formulary
13 Skin
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
13-04 Topical corticosteriods.
| Betamethasone Dipropionate 0.05% with Salicylic Acid 2% Diprosalic® |
|
Formulary
|
| Scalp application 100mL |
|
| Betamethasone Valerate 0.1% with Fucidic Acid 2% Fucibet® |
|
Formulary
|
| Cream 30g Preparations containing fusidic acid should not be used in secondary care for in-patients |
|
|
In East Lancashire| fluocinolone acetonide 0.025% with clioquinol 3% Synalar C® |
|
Formulary
|
Cream & Ointment Replaces Betnovate C cream & ointment |
|
|
| Hydrocortisone 0.5%/ nystatin 100,000units/g /benzalkonium chloride 0.2%/ dimeticone '350' 10% Timodine® |
|
Formulary
|
| Cream 30g |
|
|
| Hydrocortisone Acetate 1% with Fusidic Acid 2% Fucidin H® |
|
Formulary
|
| Cream 30g, 60g Preparations containing fusidic acid should not be used in secondary care for in-patients |
|
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Sept 21: Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
- MHRA: Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA81: Frequency of application of topical corticosteroids for atopic eczema